These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37528089)

  • 1. Inhibition of autotaxin alleviates pathological features of hepatic encephalopathy at the level of gut-liver-brain axis: an experimental and bioinformatic study.
    Sepehrinezhad A; Shahbazi A; Joghataei MT; Larsen FS; Sahab Negah S
    Cell Death Dis; 2023 Aug; 14(8):490. PubMed ID: 37528089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Autotaxin Ameliorates LPA-Mediated Neuroinflammation and Alleviates Neurological Dysfunction in Acute Hepatic Encephalopathy.
    Roy S; Chakrabarti M; Dasgupta H; Mahale A; Tripathi S; Sharma V; Banerjee M; Kulkarni OP
    ACS Chem Neurosci; 2022 Oct; 13(19):2829-2841. PubMed ID: 36112416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autotaxin-Lysophosphatidic Acid Axis Blockade Improves Inflammation by Regulating Th17 Cell Differentiation in DSS-Induced Chronic Colitis Mice.
    Dong YL; Duan XY; Liu YJ; Fan H; Xu M; Chen QY; Nan Z; Wu H; Deng SJ
    Inflammation; 2019 Oct; 42(5):1530-1541. PubMed ID: 31102124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation.
    Trovato FM; Zia R; Napoli S; Wolfer K; Huang X; Morgan PE; Husbyn H; Elgosbi M; Lucangeli M; Miquel R; Wilson I; Heaton ND; Heneghan MA; Auzinger G; Antoniades CG; Wendon JA; Patel VC; Coen M; Triantafyllou E; McPhail MJ
    Hepatology; 2021 Aug; 74(2):907-925. PubMed ID: 33908067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of Autotaxin/Autotaxin-Lysophosphatidic Acid Axis in the Initiation and Progression of Liver Cancer.
    She S; Zhang Q; Shi J; Yang F; Dai K
    Front Oncol; 2022; 12():922945. PubMed ID: 35769713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexamethasone decreases the autotaxin-lysophosphatidate-inflammatory axis in adipose tissue: implications for the metabolic syndrome and breast cancer.
    Meng G; Tang X; Yang Z; Zhao Y; Curtis JM; McMullen TPW; Brindley DN
    FASEB J; 2019 Feb; 33(2):1899-1910. PubMed ID: 30192654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Concentrations of Lysophosphatidic Acid and Autotaxin in Abstinent Patients with Alcohol Use Disorder and Comorbid Liver Disease.
    Flores-López M; García-Marchena N; Pavon FJ; Lara E; Porras-Perales O; Araos P; Requena-Ocaña N; Torres-Galván S; Mañas-Padilla MC; Rubio G; Suárez J; Santín LJ; Rodríguez de Fonseca F; Castilla-Ortega E; García-Fernández MI; Serrano A
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity.
    Watanabe N; Ikeda H; Nakamura K; Ohkawa R; Kume Y; Tomiya T; Tejima K; Nishikawa T; Arai M; Yanase M; Aoki J; Arai H; Omata M; Fujiwara K; Yatomi Y
    Life Sci; 2007 Sep; 81(12):1009-15. PubMed ID: 17850827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenteric Adipose Tissue Contributes to Intestinal Fibrosis in Crohn's Disease Through the ATX-LPA Axis.
    Huang L; Qian W; Xu Y; Guo Z; Yin Y; Guo F; Zhu W; Li Y
    J Crohns Colitis; 2022 Aug; 16(7):1124-1139. PubMed ID: 35104318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C.
    Watanabe N; Ikeda H; Nakamura K; Ohkawa R; Kume Y; Aoki J; Hama K; Okudaira S; Tanaka M; Tomiya T; Yanase M; Tejima K; Nishikawa T; Arai M; Arai H; Omata M; Fujiwara K; Yatomi Y
    J Clin Gastroenterol; 2007 Jul; 41(6):616-23. PubMed ID: 17577119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autotaxin and chronic inflammatory diseases.
    Magkrioti C; Galaris A; Kanellopoulou P; Stylianaki EA; Kaffe E; Aidinis V
    J Autoimmun; 2019 Nov; 104():102327. PubMed ID: 31471142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAPK signaling determines lysophosphatidic acid (LPA)-induced inflammation in microglia.
    Plastira I; Bernhart E; Joshi L; Koyani CN; Strohmaier H; Reicher H; Malle E; Sattler W
    J Neuroinflammation; 2020 Apr; 17(1):127. PubMed ID: 32326963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, Characterization, and
    Hunziker D; Reinehr S; Palmhof M; Wagner N; Biniasch T; Stute G; Mattei P; Schmitz P; DiGiorgio P; Hert J; Rudolph MG; Benz J; Stihle M; Gsell B; Müller S; Gasser R; Schonhoven N; Ullmer C; Joachim SC
    Front Pharmacol; 2021; 12():699535. PubMed ID: 35126098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis.
    Baader M; Bretschneider T; Broermann A; Rippmann JF; Stierstorfer B; Kuttruff CA; Mark M
    Br J Pharmacol; 2018 Feb; 175(4):693-707. PubMed ID: 29197066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
    Farquhar MJ; Humphreys IS; Rudge SA; Wilson GK; Bhattacharya B; Ciaccia M; Hu K; Zhang Q; Mailly L; Reynolds GM; Ashcroft M; Balfe P; Baumert TF; Roessler S; Wakelam MJO; McKeating JA
    J Hepatol; 2017 May; 66(5):919-929. PubMed ID: 28126468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysophosphatidic acid receptor, LPA
    Masago K; Kihara Y; Yanagida K; Hamano F; Nakagawa S; Niwa M; Shimizu T
    Biochem Biophys Res Commun; 2018 Jul; 501(4):1048-1054. PubMed ID: 29778535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of autotaxin by bile salts and bile salt-like molecules increases its expression by feedback regulation.
    Langedijk JAGM; Tolenaars D; Bolier R; Lee YT; Meurs A; Williamson C; Adorini L; van de Graaf SFJ; Beuers U; Elferink RO
    Biochim Biophys Acta Mol Basis Dis; 2021 Nov; 1867(11):166239. PubMed ID: 34389475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autotaxin-LPA signaling contributes to obesity-induced insulin resistance in muscle and impairs mitochondrial metabolism.
    D'Souza K; Nzirorera C; Cowie AM; Varghese GP; Trivedi P; Eichmann TO; Biswas D; Touaibia M; Morris AJ; Aidinis V; Kane DA; Pulinilkunnil T; Kienesberger PC
    J Lipid Res; 2018 Oct; 59(10):1805-1817. PubMed ID: 30072447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disrupted Blood-Brain Barrier and Mitochondrial Impairment by Autotaxin-Lysophosphatidic Acid Axis in Postischemic Stroke.
    Bhattarai S; Sharma S; Ara H; Subedi U; Sun G; Li C; Bhuiyan MS; Kevil C; Armstrong WP; Minvielle MT; Miriyala S; Panchatcharam M
    J Am Heart Assoc; 2021 Sep; 10(18):e021511. PubMed ID: 34514847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
    Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
    Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.